Paola Borza-Anticoli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances
Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances
Published: October 15, 2025

The Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network.

The Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network.

Journal: Cancers
Published: January 20, 2025

Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.

Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.

Journal: Journal of clinical medicine
Published: March 02, 2023

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma.

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical medicine
Published: October 22, 2022

IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.

IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.

Journal: Leukemia
Published: June 16, 2022

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.

Journal: Cancer chemotherapy and pharmacology
Published: July 04, 2020

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).

The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).

Journal: Leukemia & lymphoma
Published: July 02, 2019

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.

Journal: European journal of cancer care
Published: January 28, 2019

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Journal: British journal of haematology
Published: December 02, 2017
Showing 1-10 of 10

Last Updated: 09/26/2026